[go: up one dir, main page]

AR032642A1 - CHEMOTHERAPICAL COMPOSITIONS OF PACLITAXEL IN MICROEMULSION WITH GREATER ORAL BIODISPONIBILITY. - Google Patents

CHEMOTHERAPICAL COMPOSITIONS OF PACLITAXEL IN MICROEMULSION WITH GREATER ORAL BIODISPONIBILITY.

Info

Publication number
AR032642A1
AR032642A1 ARP020100158A ARP020100158A AR032642A1 AR 032642 A1 AR032642 A1 AR 032642A1 AR P020100158 A ARP020100158 A AR P020100158A AR P020100158 A ARP020100158 A AR P020100158A AR 032642 A1 AR032642 A1 AR 032642A1
Authority
AR
Argentina
Prior art keywords
paclitaxel
microemulsion
chemotherapical
biodisponibility
compositions
Prior art date
Application number
ARP020100158A
Other languages
Spanish (es)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of AR032642A1 publication Critical patent/AR032642A1/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composiciones farmacéuticas adecuadas para administracion oral que contienen paclitaxel, un solvente, un surfactante, un polímero celulosico sustituido y, opcionalmente pero de preferencia, un inhibidor de la glicoproteína P. La composicion puede comprender adicionalmente un diglicérido o una mezcla de diglicérido y monoglicérido. La composicion genera una microemulsion sobresaturada de paclitaxel al entrar en contacto con agua, aumentando de esta forma la biodisponibilidad oral del fármaco.Pharmaceutical compositions suitable for oral administration containing paclitaxel, a solvent, a surfactant, a substituted cellulosic polymer and, optionally but preferably, a P-glycoprotein inhibitor. The composition may additionally comprise a diglyceride or a mixture of diglyceride and monoglyceride. The composition generates a supersaturated microemulsion of paclitaxel upon contact with water, thereby increasing the oral bioavailability of the drug.

ARP020100158A 2001-01-18 2002-01-17 CHEMOTHERAPICAL COMPOSITIONS OF PACLITAXEL IN MICROEMULSION WITH GREATER ORAL BIODISPONIBILITY. AR032642A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26255501P 2001-01-18 2001-01-18

Publications (1)

Publication Number Publication Date
AR032642A1 true AR032642A1 (en) 2003-11-19

Family

ID=22998000

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100158A AR032642A1 (en) 2001-01-18 2002-01-17 CHEMOTHERAPICAL COMPOSITIONS OF PACLITAXEL IN MICROEMULSION WITH GREATER ORAL BIODISPONIBILITY.

Country Status (9)

Country Link
EP (1) EP1365759A2 (en)
JP (1) JP2004520398A (en)
AR (1) AR032642A1 (en)
CA (1) CA2434641A1 (en)
MX (1) MXPA03006404A (en)
NZ (1) NZ539046A (en)
PE (1) PE20020833A1 (en)
WO (1) WO2002064132A2 (en)
ZA (1) ZA200305086B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750246B1 (en) 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
KR100533458B1 (en) * 2002-07-20 2005-12-07 대화제약 주식회사 Composition for solubilization of paclitaxel and preparation method thereof
EP1498143A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
EP1498120A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid formulations for the oral administration of taxoids
US20050123602A1 (en) * 2003-09-25 2005-06-09 Michaelis Arthur F. Rifalazil formulations
JP2008543789A (en) * 2005-06-17 2008-12-04 ホスピラ オーストラリア ピーティーワイ エルティーディー Docetaxel liquid pharmaceutical formulation
US20100168410A1 (en) * 2006-10-27 2010-07-01 Pfizer Products Inc. Hydroxypropyl Methyl Cellulose Hard Capsules and Process of Manufacture
US20090088393A1 (en) * 2007-09-28 2009-04-02 Zomanex, Llc Methods and formulations for converting intravenous and injectable drugs into oral dosage forms
KR101053780B1 (en) * 2008-02-29 2011-08-02 동아제약주식회사 Single liquid stable pharmaceutical composition containing docetaxel
JP5868414B2 (en) * 2010-11-08 2016-02-24 カディラ ファーマシューティカルズ リミテッド Taxoid pharmaceutical composition
CN103110581B (en) * 2013-02-26 2015-07-22 西南大学 Taxol microemulsion drug composition and preparation method thereof
KR101542364B1 (en) * 2014-10-31 2015-08-07 대화제약 주식회사 Pharmaceutical composition for oral administration comprising taxanes
US10987335B2 (en) 2015-07-30 2021-04-27 Dae Hwa Pharma. Co., Ltd. Pharmaceutical composition for oral administration comprising high concentration taxane
CN107028931A (en) 2016-02-04 2017-08-11 上海宣泰医药科技有限公司 A kind of taxol drug composition and its pharmaceutical preparation, preparation method and purposes
EP3701943A1 (en) * 2019-02-26 2020-09-02 CAPNOMED GmbH Delayed delivery of anticancer drugs
KR20250002778A (en) * 2022-05-11 2025-01-07 일라이 릴리 앤드 캄파니 GLP1 pharmaceutical composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
WO1998013359A1 (en) * 1996-09-24 1998-04-02 Marigen S.A. Ultramicroemulsion of spontaneously dispersible concentrates of esters of baccatin-iii compounds with antitumor and antiviral effect
CH688504A5 (en) * 1997-03-26 1997-10-31 Marigen Sa Spontaneously dispersible concentrate containing a taxol analogue
PL337064A1 (en) * 1997-05-27 2000-07-31 Baker Norton Pharma Method of and compositions for orally administering taxanes to human beings
WO1998058927A1 (en) * 1997-06-20 1998-12-30 Baker Norton Pharmaceuticals, Inc. Soluble prodrugs of paclitaxel
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
CN1236813C (en) * 1998-12-11 2006-01-18 药品处理公司 Self-emulsifying compositions for drugs poorly soluble in water
EP1180020B2 (en) * 1999-05-27 2009-06-24 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
WO2002043765A2 (en) * 2000-11-28 2002-06-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof

Also Published As

Publication number Publication date
WO2002064132A2 (en) 2002-08-22
EP1365759A2 (en) 2003-12-03
WO2002064132A3 (en) 2003-05-30
JP2004520398A (en) 2004-07-08
NZ539046A (en) 2006-11-30
CA2434641A1 (en) 2002-08-22
PE20020833A1 (en) 2002-09-19
MXPA03006404A (en) 2004-12-02
ZA200305086B (en) 2004-06-30

Similar Documents

Publication Publication Date Title
AR032642A1 (en) CHEMOTHERAPICAL COMPOSITIONS OF PACLITAXEL IN MICROEMULSION WITH GREATER ORAL BIODISPONIBILITY.
AR037490A1 (en) SOLID PHARMACEUTICAL COMPOSITIONS, PROCESS FOR PREPARATION, KIT FOR THE TREATMENT OF OBESITY AND USE OF SUCH COMPOSITIONS IN THE DEVELOPMENT OF MEDICINES
AR027091A1 (en) DOSAGE FORM OF DRUGS DRIVEN BY A HYDROGEL
CL2008002406A1 (en) Oral dissolving film composition comprising a cosmetic or pharmaceutical active agent, and a polyvinyl alcohol-polyethylene glycol graft copolymer (application divisional 1825-04).
ES2167061T3 (en) DOSAGE FORMS TO IMPROVE ERECTILE DYSFUNCTION IN MALE SEX PATIENTS.
AR023228A1 (en) STABLE FOAM COMPOSITIONS
BR0112054A (en) Micelle-forming composition, and methods for administration and protection of a therapeutic agent
SV2004001556A (en) ACID PREPARATIONS OF INSULIN WITH IMPROVED STABILITY
BR0215184A (en) orally active taxane derivative pharmaceutical compositions having increased bioavailability
AR046811A1 (en) ORAL DOSAGE FORMS OF ZIPRASIDONE OF SUSTAINED LIBERATION
AR029763A1 (en) USE OF A COMBINATION OF AN NSAID AND AN EGFR QUINASA INHIBITOR FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OR INHIBITION OF COLONIC POLYPS AND COLORECTAL CANCER, PHARMACEUTICAL COMPOSITION AND MEDICINAL PRODUCT
CO5560580A2 (en) FORMULATIONS OF SUCRALOSE TO DISPENSE FLAVORABLE FLAVORS
NO330947B1 (en) The use of oxcarbazepine-containing pharmaceutical compositions in the fasted state
ECSP083351A (en) PHARMACEUTICAL COMPOSITIONS
AR034231A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING MOSAPRIDE AND PANCREATIN
ES2192234T3 (en) PARENTERAL PHARMACEUTICAL COMPOSITIONS CONTAINING SALTS OF 2-ARILPROPIONIC ACIDS.
AR109263A2 (en) COMPOSITION INCLUDING MOXIDECTINE
AR021934A1 (en) COMPOSITION OF ORAL ADMINISTRATION WITH CONTROLLED RELEASE OF AT LEAST ONE ANALGESIC
AR027360A1 (en) PHARMACEUTICAL COMPOSITION
CL2007003010A1 (en) Oral dosage form comprising an erodible core that contains an active principle of a weak basic character, an erodible coating around said core with one or more openings that pass through the coating and connect the core with the means of use; preparation procedure; and use (divisional of 260-03).
AR046402A1 (en) COMBINATION OF ACTIVE PRINCIPLE THAT INCLUDES A 2,5-DIHYDROBENCENOSULPHONIC COMPOUND AND A POTASSIUM CHANNEL MODULATOR
UY26171A1 (en) PHARMACEUTICAL FORMULATION AND METHOD FOR THE TREATMENT OF LATE APPEARANCE DYSKINESIA
CY1110478T1 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF A PYRAZOLO-3-CARBOXAMIDE PRODUCER
ATE297760T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING TERBINAFIN
AR043370A1 (en) PHARMACEUTICAL COMPOSITIONS OF ORAL ADMINISTRATION AND METHODS TO AVOID FOOD-DRUG INTERACTION

Legal Events

Date Code Title Description
FB Suspension of granting procedure